Cargando…
Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial
BACKGROUND: Women with HIV face an increased risk of preterm birth. 17 alpha-hydroxyprogesterone caproate (17P) has been shown in some trials to reduce early delivery among women with a history of spontaneous preterm birth. We investigated whether 17P would reduce this risk among women with HIV. MET...
Autores principales: | Price, Joan T, Vwalika, Bellington, Freeman, Bethany L, Cole, Stephen R, Saha, Pooja T, Mbewe, Felistas M, Phiri, Winifreda M, Peterson, Marc, Muyangwa, Dorothy, Sindano, Ntazana, Mwape, Humphrey, Smithmyer, Megan E, Kasaro, Margaret P, Rouse, Dwight J, Goldenberg, Robert L, Chomba, Elwyn, Stringer, Jeffrey S A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476342/ https://www.ncbi.nlm.nih.gov/pubmed/34509197 http://dx.doi.org/10.1016/S2352-3018(21)00150-8 |
Ejemplares similares
-
Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial
por: Price, Joan T., et al.
Publicado: (2019) -
Adverse birth outcomes and their clinical phenotypes in an urban Zambian cohort
por: Price, Joan T, et al.
Publicado: (2020) -
The Zambian Preterm Birth Prevention Study (ZAPPS): Cohort characteristics at enrollment
por: Castillo, Marcela C., et al.
Publicado: (2019) -
Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection
por: Chollet, John L., et al.
Publicado: (2012) -
Pharmacokinetics of Hydroxyprogesterone Caproate and its Primary Metabolites during Pregnancy
por: Boggess, Kim A., et al.
Publicado: (2018)